Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
- Registration Number
- NCT06327269
- Lead Sponsor
- Chang Gung Memorial Hospital
- Brief Summary
The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A new generation of targeted therapies and adjuvant therapy after LDLT. Lenvatinib 10 mg The proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. Lenvatinib is applied to adjuvant therapy after LDLT. prolong the recurrence-free survival to high risk of HCC after LDLT Lenvatinib 10 mg Lenvatinib which is applied to adjuvant therapy after LDLT may prolong the recurrence-free survival
- Primary Outcome Measures
Name Time Method Recurrence-free survival with adjuvant therapy 2 years Lenvatinib treatment may prolong the recurrence-free survival rate after LDLT.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Surgery
🇨🇳Kaohsiung, Taiwan